Table 1. Summary of completed NSCLC immunotherapy trials.
| Immunotherapy | Target | Pt No. | Stage | Results |
|---|---|---|---|---|
| Stage I-III disease | ||||
| MAGE-A3 | MAGE-A3 | 182 | IB/II following complete resection | HR for DFS =0.76 (95% CI: 0.48-1.21), HR for OS =0.81 (95% CI: 0.47-1.40) with MAGE-A3 compared to SOC (5) |
| Stage IIIB-IV disease | ||||
| BLP-25 | MUC1 | 171 | IIIB/IV after 1st line chemotherapy | 3 yr. OS 31% for BLP-25 and 17% for BSC (P=0.035) Stage IIIB subset MS 30.6 months for BLP-25 vs. 13.3 months for BSC (HR =0.548, 95% CI: 0.301-0.999) (6,7) |
| Belagenpimatucel-L | TGF-β2 | 75 | II/IIIA/IIIB/IV after completion of therapy | Superior MS for high vaccine doses group vs. low vaccine doses group (P=0.0069) (8) |
| EGF | Epidermal growth factor | 80 | IIIB/IV after first-line chemotherapy | MS 11.7 months with GAR and 3.6 months with PAR (P=0.0002) (9) |
| TG4010 | MUC1 | 148 | IIIB/IV with 1st line chemotherapy | 6-months PFS 43.2% for TG4010 vs. 35.1% for chemotherapy alone (P=0.307) (10) |
| Ipilimumab | CTLA-4 | 204 | IIIB/IV or recurrent disease in combination with first-line chemotherapy | Immune-related PFS 5.7 months for phased ipilimumab + chemotherapy vs. 4.6 months for placebo + chemotherapy (HR 0.72; P=0.05) (11) |
| Nivolumab | PD-1 | 296 (122 NSCLC) | IV after completion of first-line chemotherapy | OR in 6 (33%) out of 18 with squamous cell histology; OR in 7 (12%) out of 56 with nonsquamous histology (12) |
| BMS-936559 | PD-L1 | 207 (75 NSCLC) | IV after completion of first-line chemotherapy | OR in 4 (11%) of 36 nonsquamous histology; OR in 1 (8%) of 13 squamous histology (13) |
BSC, best supportive care; GAR, good antibody response; HR, hazard ration; MS, median survival; NSCLC, non-small cell lung cancer; OR, overall response; PAR, poor antibody response; PFS, progression-free survival; Pt, patients; RR, response rate; SOC, standard of care.